Stockscreener 앱 받기
60.56
0.35%
-0.21
시간 외 거래:
60.65
0.09
+0.15%
전일 마감가:
$60.77
열려 있는:
$60.77
하루 거래량:
628.81K
Relative Volume:
0.48
시가총액:
$5.86B
수익:
$7.50M
순이익/손실:
$-383.17M
주가수익비율:
-12.87
EPS:
-4.7048
순현금흐름:
$-307.84M
1주 성능:
-2.89%
1개월 성능:
-7.43%
6개월 성능:
+35.21%
1년 성능:
+55.92%
1일 변동 폭
$60.00
$61.05
1주일 범위
$59.27
$64.93
52주 변동 폭
$35.60
$72.66
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
명칭
Xenon Pharmaceuticals Inc
전화
(604) 484-3300
주소
200 - 3650 GILMORE WAY, BURNABY
Compare XENE vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
60.56 | 5.78B | 7.50M | -383.17M | -307.84M | -4.7048 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2025-09-03 | 재개 | Wells Fargo | Overweight |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-10-01 | 개시 | H.C. Wainwright | Buy |
| 2024-01-04 | 개시 | Citigroup | Buy |
| 2023-12-08 | 개시 | Robert W. Baird | Outperform |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-04-25 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-14 | 개시 | Goldman | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-10-19 | 개시 | Raymond James | Outperform |
| 2022-08-29 | 개시 | BofA Securities | Buy |
| 2022-07-21 | 개시 | JP Morgan | Overweight |
| 2021-10-28 | 개시 | RBC Capital Mkts | Outperform |
| 2020-10-02 | 개시 | SVB Leerink | Outperform |
| 2020-07-21 | 개시 | Needham | Buy |
| 2020-06-01 | 재개 | Jefferies | Buy |
| 2020-03-25 | 개시 | Wedbush | Outperform |
| 2020-01-08 | 개시 | William Blair | Outperform |
| 2019-09-20 | 개시 | Guggenheim | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2017-03-13 | 개시 | Jefferies | Buy |
| 2016-10-21 | 개시 | Stifel | Buy |
| 2016-09-26 | 개시 | Guggenheim | Buy |
| 2016-04-14 | 재확인 | Jefferies | Buy |
| 2015-10-30 | 재개 | Jefferies | Buy |
| 2014-12-02 | 개시 | Canaccord Genuity | Buy |
모두보기
Xenon Pharmaceuticals Inc 주식(XENE)의 최신 뉴스
Bank of America Corp DE Increases Stock Holdings in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon (XENE) Today: Ends Down by 4.16% at $59.73 for the Current Session; Technical Setup: Support at $56.74 and Resistance at $62.72 Frame the Range under the Current SnapshotMcClellan Oscillator - Vinanet
Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript - AOL.com
Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors? - simplywall.st
Xenon Pharmaceuticals (XENE) Holds Steady at $62.36 as Shares Consolidate Below Key ResistanceIV Rank - vinanet.vn
TimesSquare Capital Management LLC Purchases Shares of 451,593 Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals (XENE) Could Be 23% Undervalued As Epilepsy Growth Narrative Holds - Sahm
Xenon Pharmaceuticals (XENE) Pulls Back 2.93% as Shares Approach Critical SupportCall Wall - vinanet.vn
Xenon Pharmaceuticals Independent Director Steven Gannon Sells 84% Of Holding - simplywall.st
Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE - MarketBeat
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xenon Pharmaceuticals (XENE) Insider Sells 10,000 Shares; Direct - GuruFocus
(XENE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Xenon Pharmaceuticals (NASDAQ:XENE) Director Sells 10,000 Shares of Stock - MarketBeat
Xenon Pharmaceuticals (XENE) director sells 10,000 common shares at $64 - Stock Titan
Xenon Pharmaceuticals Insider Sold Shares Worth $640,550, According to a Recent SEC Filing - marketscreener.com
Xenon Pharmaceuticals Director Sold Shares Worth Over $640K - TradingView
Seller for XENE (NASDAQ: XENE) plans 10,000-share common stock sale - Stock Titan
Wellington group discloses 1.47% Xenon Pharmaceuticals (XENE) stake for advisory clients - Stock Titan
Xenon Pharmaceuticals (NASDAQ:XENE) Presents High-Quality Technical Breakout Setup - ChartMill
Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity (XENE) - Seeking Alpha
HC Wainwright Issues Positive Outlook for XENE Earnings - MarketBeat
Xenon Pharmaceuticals Inc. (XENE): Analyst Consensus Highlights 26.65% Potential Upside - DirectorsTalk Interviews
H.C. Wainwright reiterates Xenon Pharmaceuticals stock rating at buy - Investing.com
H.C. Wainwright reiterates Xenon Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Brokers Issue Forecasts for XENE Q1 Earnings - MarketBeat
Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE - MarketBeat
FDA Pre-NDA Progress On Azetukalner Could Be A Game Changer For Xenon Pharmaceuticals (XENE) - webull.com
Xenon Pharmaceuticals Stock Price Forecast. Should You Buy XENE? - StockInvest.us
A Quick Look at Today's Ratings for Xenon Pharmaceuticals(XENE.US), With a Forecast Between $81 to $90 - Moomoo
H.C. Wainwright Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $74 - Moomoo
XENE Maintained by RBC Capital -- Price Target Lowered to $81.00 - GuruFocus
Xenon Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Wedbush Adjusts PTon Xenon Pharmaceuticals to $71 From $63, Maintains Outperform Rating - Moomoo
Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says - marketscreener.com
Xenon Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $81.21, Implies 26% Upside - TradingView
FMR LLC (XENE) discloses 9.96M-share, 10.3% holding in Xenon Pharmaceuticals - Stock Titan
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus - Yahoo Finance
RBC Adjusts Xenon Pharmaceuticals PT to $81 From $82, Maintains Outperform Speculative Risk Rating - marketscreener.com
Xenon Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
California State Teachers Retirement System Buys 36,183 Shares of Xenon Pharmaceuticals Inc. $XENE - marketbeat.com
Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results - MarketBeat
Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ... - Yahoo! Finance Canada
Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlig - GuruFocus
XENON PHARMACEUTICALS INC. : WEDBUSH RAISES TARGET PRICE TO $71 FROM $63 - Bitget
XENE Advances Pipeline with NDA Submission Plans Amid High Price-to-Sales Valuation - GuruFocus
Xenon Pharmaceuticals Q2 Loss Widens - marketscreener.com
Earnings Flash (XENE) Xenon Posts Q2 Loss Per Share $1.11, vs. FactSet Est of $1.14 Loss - marketscreener.com
Xenon Pharmaceuticals Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Xenon Pharmaceuticals Inc. Q2 2026: Revenue $0 EPS $(1.11) — 10-Q Summary - TradingView
Xenon Pharmaceuticals Inc. R (XP0.F) Q2 FY2026 earnings call transcript - Yahoo Finance
Xenon Pharmaceuticals Inc (XENE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):